Advancement of pharmacological effects of xanthones in the cardiovascular system

Abstract

Abstract: Xanthones are a class of polyphenolic compounds that commonly occur in plants and have been shown to have extensive biological and pharmacological activities. Recently, the pharmacological properties of xanthone derivatives have been shown to have beneficial effects on some cardiovascular diseases, including ischemic heart disease, atherosclerosis, hypertension and thrombosis. The protective effects of xanthones in the cardiovascular system may be due to their antioxidant, anti-inflammatory, endothelial protective, platelet aggregation inhibitory, antithrombotic and vasorelaxant activities.

Key words: xanthone, pharmacology, cardiovascular disease

CLC Number:

R969

LIU Si-yu, SHI Rui-zheng, FAN Ruo-hao, JIANG De-jian. Advancement of pharmacological effects of xanthones in the cardiovascular system[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1304-1308.

References

[1] Jiang DJ, Tan GS, Ye F, et al. Protective effects of xanthones against myocardial ischemia-reperfusion injury in rats[J]. Acta Pharmacol Sin, 2003, 24(2): 175-180.
[2] Jiang DJ, Tan GS, Zhou ZH, et al. Protective effects of demethylbellidifolin on myocardial ischemia-reperfusion injury in rats[J]. Planta Med, 2002, 68(8): 710-713.
[3] Muruganandan S, Gupta S, Kataria M, et al. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats[J]. Toxicology, 2002, 176(3): 165-173.
[4] Shen JG, Quo XS, Jiang B, et al. Chinonin, a novel drug against cardiomyocyte apoptosis induced by hypoxia and reoxygenation[J]. Biochim Biophys Acta, 2000, 1500(2): 217-226.
[5] Zhao B, Shen J, Li M, et al. Scavenging effect of Chinonin on NO and oxygen free radicals and its protective effect on the myocardium from the injury of ischemia-reperfusion[J]. Biochim Biophys Acta, 1996, 1315(2): 131-137.
[6] Leiro JM, Alvarez E, Arranz JA, et al. In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factoralpha and transforming growth factor-beta genes[J]. Biochem Pharmacol, 2003, 65(8): 1361-1371.
[7] Chiang YM, Kuo YH, Oota S, et al. Xanthones and Benzophenones from the Stems of Garcinia multiflora[J]. J Nat Prod, 2003, 66(8): 1070-1073.
[8] Jiang DJ, Jiang JL, Tan GS, et al. Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine[J]. N-S Arch Pharmacol, 2003, 367(6): 600-606.
[9] Lee HZ, Lin WC, Yeh FT, et al. Decreased protein kinase C activation mediates inhibitory effect of norathyriol on serotonin-mediated endothelial permeability[J]. Eur J Pharmacol, 1998, 353(2 3): 303-313.
[10] Madan B, Singh I, Kumar A, et al. Xanthones as inhibitors of microsomal lipid peroxidation and TNF-alpha induced ICAM-1 expression on human umbilical vein endothelial cells (HUVECs)[J]. Bioorg Med Chem, 2002, 10(11): 3431-3436.
[11] Dai Z, Jiang DJ, Hu GY, et al. 3, 4, 5, 6-tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats[J]. Cardiovasc Drug Ther, 2004, 18(4): 279-288.
[12] 贾素洁, 李元建. 口山酮对高胆固醇血症大鼠血脂的影响[J]. 中国动脉硬化杂志, 2005, 13(3): 317-319.
[13] 肖红波, 李年生, 贾素洁, 等. 3, 4, 5, 6-四羟基口山酮抑制ApoE-基因缺陷小鼠动脉粥样硬化形成及机制[J]. 国际病理科学与临床杂志, 2006, 26(3): 185-189.
[14] Jiang DJ, Jiang JL, Zhu HQ, et al. Demethylbellidifolin preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level[J]. J Ethnopharmacol, 2004, 93(2/3): 295-306.
[15] Jiang DJ, Hu GY, Jiang JL, et al. Relationship between protective effect of xanthone on endothelial cells and endogenous nitric oxide synthase inhibitors[J]. Bioorg Med Chem, 2003, 11(23): 5171-5177.
[16] Jiang DJ, Jiang JL, Tan GS, et al. Demethylbellidifolin inhibits adhesion of monocytes to endothelial cells via reduction of endogenous nitric oxide synthase inhibitor level[J]. Planta Med, 2003, 69(12): 1150-1152.
[17] Leiro JM, Alvarez E, Arranz JA, et al. In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factoralpha and transforming growth factor-beta genes[J]. Biochem Pharmacol, 2003, 65(8): 1361-1371.
[18] 姜德建, 李元建. 非对称性二甲基精氨酸—新的心血管疾病危险因子和药物防治靶点[J]. 中国动脉硬化杂志, 2005, 13(3): 379-382.
[19] Chericoni S, Testai L, Calderone V, et al. The Xanthones gentiacaulein and gentiakochianin are responsible for the vasodilator action of the roots of Gentiana kochiana[J]. Planta Med, 2003, 69(8): 770-772.
[20] Wang LW, Kang JJ, Chen IJ, et al. Antihypertensive and vasorelaxing activities of synthetic xanthone derivatives[J]. Bioorg Med Chem, 2002, 10(3): 567-572.
[21] Wang Y, Shi JG, Wang MZ, et al. Mechanisms of the vasorelaxant effect of 1-hydroxy-2, 3, 5-trimethoxy-xanthone, isolated from a Tibetan herb, Halenia elliptica, on rat coronary artery[J]. Life Sciences, 2007, 81(12): 1016-1023.
[22] Rajtar G, Zolkowska D, Kleinrok Z, et al. Antiplatelets activity of some xanthone derivatives[J]. Acta Pol Pharm, 1999, 56(4): 319-324.
[23] Lin CN, Liou SS, Ko FN, et al. Gamma-pyrone compounds. II: Synthesis and antiplatelet effects of tetraoxygenated xanthones[J]. J Pharm Sci, 1992, 81(11): 1109-1112.
[24] Jantan I, Pisar MM, Idris MS, et al. In vitro inhibitory effect of rubraxanthone isolated from Garcinia parvifolia on platelet-activating factor receptor binding[J]. Planta Med, 2002, 68(12): 1133-1134.
[25] Ishiguro K, Nagata S, Oku H, et al. Bisxanthones from Hypericum japonicum:inhibitors of PAF-induced hypotension[J]. Planta Med, 2002, 68(3): 258-261.